Changes in inpatient treatment of Clostridioides difficile infection in a US electronic health record network, 2019–2025

Objective: To describe inpatient Clostridioides difficile infection (CDI) treatment, factors associated with fidaxomicin selection, and discharge prescribing. Design: Retrospective cohort study. Setting: A US electronic health record network, 2019–2025. Patients: Adults with CDI-coded hospital admissions supported by a qualifying laboratory result or enteral treatment. Methods: We described treatment for every study year, including multiple-agent regimens and absent treatment capture. Post-June 2021 analyses compared fidaxomicin and enteral-vancomycin recipients, adjusted for patient characteristics and calendar quarter, and examined discharge prescriptions. Sensitivities considered recorded data sources, laboratory support, and recurrence ascertainment. Results: Analyses included 507,855 episodes. Initial fidaxomicin use increased from 4.4% in 2019 to 18.9% in 2025; enteral vancomycin remained predominant (76.5% in 2025). No qualifying initial treatment was captured in 15.5% and 6.3%, respectively. Among 262,592 post-update episodes meeting treatment-timing criteria, prior CDI, immunocompromising-condition codes, and transplant codes were associated with fidaxomicin selection; these associations persisted after source adjustment. Among 43,394 surviving, valid-stay episodes initially receiving fidaxomicin alone, 5,256 (12.1%) had a vancomycin-only discharge prescription; 28.4% had no qualifying outpatient prescription captured. Recorded recurrence depended on the definition and follow-up denominator. Conclusions: Fidaxomicin uptake increased, but enteral vancomycin remained predominant. Transitions from initial fidaxomicin to vancomycin at discharge highlight a care-transition question without establishing insurance-related causation. These data describe prescribing and ascertainment, not guideline effectiveness or comparative drug benefit.

Authors

Institutions

Publication Details

Journal
Antimicrobial Stewardship & Healthcare Epidemiology
Published
2026-11-19
DOI
https://doi.org/10.1017/ash.2026.10963
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Changes in inpatient treatment of Clostridioides difficile infection in a US electronic health record network, 2019–2025

Todd Michael Lasco, Mayar Al Mohajer, Shreya Jain, Angela X. Wu et al.
Antimicrobial Stewardship & Healthcare Epidemiology
Clostridium difficile and Clostridium perfringens research
article

Changes in inpatient treatment of Clostridioides difficile infection in a US electronic health record network, 2019–2025

Todd Michael Lasco, Mayar Al Mohajer, Shreya Jain, Angela X. Wu, Mujeeb A. Basit
article en

Abstract

Objective: To describe inpatient Clostridioides difficile infection (CDI) treatment, factors associated with fidaxomicin selection, and discharge prescribing. Design: Retrospective cohort study. Setting: A US electronic health record network, 2019–2025. Patients: Adults with CDI-coded hospital admissions supported by a qualifying laboratory result or enteral treatment. Methods: We described treatment for every study year, including multiple-agent regimens and absent treatment capture. Post-June 2021 analyses compared fidaxomicin and enteral-vancomycin recipients, adjusted for patient characteristics and calendar quarter, and examined discharge prescriptions. Sensitivities considered recorded data sources, laboratory support, and recurrence ascertainment. Results: Analyses included 507,855 episodes. Initial fidaxomicin use increased from 4.4% in 2019 to 18.9% in 2025; enteral vancomycin remained predominant (76.5% in 2025). No qualifying initial treatment was captured in 15.5% and 6.3%, respectively. Among 262,592 post-update episodes meeting treatment-timing criteria, prior CDI, immunocompromising-condition codes, and transplant codes were associated with fidaxomicin selection; these associations persisted after source adjustment. Among 43,394 surviving, valid-stay episodes initially receiving fidaxomicin alone, 5,256 (12.1%) had a vancomycin-only discharge prescription; 28.4% had no qualifying outpatient prescription captured. Recorded recurrence depended on the definition and follow-up denominator. Conclusions: Fidaxomicin uptake increased, but enteral vancomycin remained predominant. Transitions from initial fidaxomicin to vancomycin at discharge highlight a care-transition question without establishing insurance-related causation. These data describe prescribing and ascertainment, not guideline effectiveness or comparative drug benefit.

Antimicrobial Stewardship & Healthcare EpidemiologyVol. 6(1)
Baylor College of Medicine (US), University of Oxford (GB), The University of Texas Southwestern Medical Center (US)
Clostridium difficile and Clostridium perfringens research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon